Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyril Šálek

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biological Procedures Online|October 5, 2019
DNA Methylation Validation Methods: a Coherent Review with Practical ComparisonŠárka Šestáková, Cyril Šálek, Hana Remešová
Frontiers in Oncology|May 23, 2022
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesKamila Polgárová, Pavel Otáhal, Cyril Šálek, et al.
International Journal of Molecular Sciences|June 13, 2019
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant <i>NPM1</i> and <i>FLT3</i> MutationsBarbora Brodská, Petra Otevřelová, Cyril Šálek, et al.
Folia Biologica|April 14, 2026
To the Maximal Nuclear Diameter and Cell Cycle Phase of Lymphoblasts or Myeloblasts in Patients Suffering from Acute Lymphoblastic and Myeloblastic Leukaemia. A Simple Morphological and Technical NoteKarel Smetana, Hana Klamová, Radka Šimečková, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2020
WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid LeukemiaCyril Šálek, Jan Vydra, Ela Cerovská, et al.
European Journal of Haematology|May 22, 2015
Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemiaCyril Šálek, František Folber, Eva Froňková, et al.
Oncoimmunology|May 13, 2022
<i>NPM1</i> and <i>DNMT3A</i> mutations are associated with distinct blast immunophenotype in acute myeloid leukemiaKateřina Kuželová, Barbora Brodská, Jana Marková, et al.
Clinical Epigenetics|January 23, 2024
MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemiaŠárka Šestáková, Cyril Šálek, Dávid Kundrát, et al.
Clinical Epigenetics|February 12, 2022
A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panelŠárka Šestáková, Ela Cerovská, Cyril Šálek, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2018
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete RemissionJan Vydra, Cyril Šálek, Jiří Schwarz, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biological Procedures Online|October 5, 2019
DNA Methylation Validation Methods: a Coherent Review with Practical ComparisonŠárka Šestáková, Cyril Šálek, Hana Remešová
Frontiers in Oncology|May 23, 2022
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesKamila Polgárová, Pavel Otáhal, Cyril Šálek, et al.
International Journal of Molecular Sciences|June 13, 2019
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant <i>NPM1</i> and <i>FLT3</i> MutationsBarbora Brodská, Petra Otevřelová, Cyril Šálek, et al.
Folia Biologica|April 14, 2026
To the Maximal Nuclear Diameter and Cell Cycle Phase of Lymphoblasts or Myeloblasts in Patients Suffering from Acute Lymphoblastic and Myeloblastic Leukaemia. A Simple Morphological and Technical NoteKarel Smetana, Hana Klamová, Radka Šimečková, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2020
WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid LeukemiaCyril Šálek, Jan Vydra, Ela Cerovská, et al.
European Journal of Haematology|May 22, 2015
Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemiaCyril Šálek, František Folber, Eva Froňková, et al.
Oncoimmunology|May 13, 2022
<i>NPM1</i> and <i>DNMT3A</i> mutations are associated with distinct blast immunophenotype in acute myeloid leukemiaKateřina Kuželová, Barbora Brodská, Jana Marková, et al.
Clinical Epigenetics|January 23, 2024
MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemiaŠárka Šestáková, Cyril Šálek, Dávid Kundrát, et al.
Clinical Epigenetics|February 12, 2022
A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panelŠárka Šestáková, Ela Cerovská, Cyril Šálek, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2018
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete RemissionJan Vydra, Cyril Šálek, Jiří Schwarz, et al.
Pageof 2